Inactive Instrument

News POZEN Inc.

Stocks

US73941U1025

Pharmaceuticals

End-of-day quote Nasdaq
- ^USD	-

All News

Mentions Relevance

16-02-02	POZEN : Announces Stockholder Approval of its Transaction with Tribute Pharmaceuticals Canada Inc.	PR
15-12-07	POZEN : And Tribute Announce Plan To Proceed With Merger To Form Aralez Pharmaceuticals	PR
15-12-07	POZEN : and Tribute Announce Plan to Proceed With Merger to Form Aralez Pharmaceuticals	MW
15-11-09	POZEN : Reports Third Quarter 2015 Results	BU
15-11-06	POZEN : and Tribute Announce Effectiveness of Registration Statement on Form S-4	BU
15-10-26	POZEN : to Announce Third Quarter 2015 Results on November 9, 2015	BU
15-09-15	POZEN : to Present at the Ladenburg Thalmann Healthcare Conference	BU
15-09-14	POZEN : Appoints James P. Tursi, M.D. Chief Medical Officer	BU
15-08-10	POZEN : Reports Second Quarter 2015 Results	BU
15-07-30	POZEN : Market Updates on Drug Manufacturers - Other Equities -- Isis Pharma, Endo Intl., Amarin, United Therapeutics, and POZEN	PR
15-07-27	POZEN : Announces August 10th Webcast of Second Quarter 2015 Results	BU
15-07-27	POZEN : Appoints Scott Charles Senior Vice President of Finance	BU
15-06-22	POZEN : Announces Key Leadership Additions	BU
15-06-08	POZEN : Announces Strategic Acquisition of Tribute and Growth Capital Commitment from Leading Healthcare Sponsors	MW
15-06-08	POZEN : Announces Strategic Acquisition of Tribute and Growth Capital Commitment from Leading Healthcare Sponsors	BU
15-06-02	POZEN : Forms an Irish Subsidiary and Enters into an Intangible Property Transfer Arrangement	BU
15-06-01	POZEN : Announces Retirement of Founder, Chairman and CEO Dr. John R. Plachetka; Adrian Adams Named as CEO	BU
15-05-08	POZEN : Reports First Quarter 2015 Results	PU
15-05-08	POZEN : Reports First Quarter 2015 Results	BU
15-05-04	POZEN : Announces May 8th Webcast of First Quarter 2015 Results	BU
15-03-09	POZEN : Reports Fourth Quarter and Year End 2014 Results	BU
15-03-04	POZEN : Announces March 9th Webcast of Fourth Quarter and Year End 2014 Results	BU
15-02-04	POZEN : Announces Issuance of VIMOVO® Related Patent by the United States Patent and Trademark Office	BU
14-12-17	POZEN : YOSPRALA™ Receives Complete Response Letter from The FDA	BU
14-12-01	POZEN : and Sanofi US Mutually Agree to Terminate U.S. Partnership for PA8140/PA32540	BU